Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230

Halle C.F. Moore, Joseph M. Unger, Kelly Anne Phillips, Frances Boyle, Erika Hitre, Anna Moseley, David J. Porter, Prudence A. Francis, Lori J. Goldstein, Henry L. Gomez, Carlos S. Vallejos, Ann H. Partridge, Shaker R. Dakhil, Agustin A. Garcia, Julie R. Gralow, Janine M. Lombard, John F. Forbes, Silvana Martino, William E. Barlow, Carol J. FabianLori M. Minasian, Frank L. Meyskens, Richard D. Gelber, Gabriel N. Hortobagyi, Kathy S. Albain

Research output: Article

11 Citations (Scopus)

Abstract

Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen. All statistical tests were two-sided. Of 257 patients, 218 were eligible and evaluable (105 in the chemotherapy + goserelin arm and 113 in the chemotherapy arm). More patients in the chemotherapy + goserelin arm reported at least one pregnancy vs the chemotherapy arm (5-year cumulative incidence = 23.1%, 95% confidence interval [CI] = 15.3% to 31.9%; and 12.2%, 95% CI = 6.8% to 19.2%, respectively; odds ratio = 2.34; 95% CI = 1.07 to 5.11; P=.03). Randomization to goserelin + chemotherapy was associated with a nonstatistically significant improvement in disease-free survival (hazard ratio [HR] = 0.55; 95% CI = 0.27 to 1.10; P=.09) and overall survival (HR = 0.45; 95% CI = 0.19 to 1.04; P=.06). In this long-term analysis of POEMS/S0230, we found continued evidence that patients randomly assigned to receive goserelin + chemotherapy were not only more likely to avoid premature menopause, but were also more likely to become pregnant without adverse effect on disease-related outcomes.

Original languageEnglish
Pages (from-to)210-213
Number of pages4
JournalJournal of the National Cancer Institute
Volume111
Issue number2
DOIs
Publication statusPublished - jan. 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230'. Together they form a unique fingerprint.

  • Cite this

    Moore, H. C. F., Unger, J. M., Phillips, K. A., Boyle, F., Hitre, E., Moseley, A., Porter, D. J., Francis, P. A., Goldstein, L. J., Gomez, H. L., Vallejos, C. S., Partridge, A. H., Dakhil, S. R., Garcia, A. A., Gralow, J. R., Lombard, J. M., Forbes, J. F., Martino, S., Barlow, W. E., ... Albain, K. S. (2019). Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. Journal of the National Cancer Institute, 111(2), 210-213. https://doi.org/10.1093/jnci/djy185